EGFR and non-small cell lung carcinoma: The ADAURA study (NCT02511106) also reported the advantage of osimertinib in DFS of completely resected early-stage (stage II to IIIA) NSCLC patients with EGFR mutation-positive (not reached vs 19.6 months; HR = 0.17, 99.06% CI: 0.11–0.26, p < 0.001) (12).